4 mg CLS-TA Suprachoriodal Injection
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uveitis
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Trial Timeline
Apr 4, 2017 → Jan 24, 2018
NCT ID
NCT03097315About 4 mg CLS-TA Suprachoriodal Injection
4 mg CLS-TA Suprachoriodal Injection is a phase 3 stage product being developed by Clearside Biomedical for Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03097315. Target conditions include Uveitis, Uveitis, Posterior, Uveitis, Anterior.
What happened to similar drugs?
3 of 20 similar drugs in Uveitis were approved
Approved (3) Terminated (9) Active (8)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03097315 | Phase 3 | Completed |
Competing Products
20 competing products in Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| triamcinolone acetonide (Triesence®) | Clearside Biomedical | Phase 1/2 | 22 |
| Baricitinib + Adalimumab | Eli Lilly | Phase 3 | 44 |
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 39 |
| adalimumab | AbbVie | Phase 3 | 40 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 40 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 40 |
| Adalimumab | AbbVie | Approved | 43 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 27 |
| AIN457 | Novartis | Phase 3 | 32 |
| Myfortic | Novartis | Pre-clinical | 22 |
| AIN457 + AIN457 + Placebo AIN457 | Novartis | Phase 3 | 32 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 35 |
| Ranibizumab | Novartis | Phase 2 | 35 |
| AIN457 + Placebo | Novartis | Phase 3 | 32 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 32 |
| AEB071 | Novartis | Phase 2 | 35 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 32 |
| Myfortic + Decortin | Novartis | Phase 3 | 40 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 35 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 32 |